Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2000

View Archived Issues

Medarex and Eos Biotechnology establish genomics-based antibody drug alliance

NCI extends two CRADAs with Therion Biologics for cancer vaccines

Kyowa Hakko and Geron extend telomerase partnership

Phase III study of ALX1-11 now under way for treatment of osteoporosis

Novel gene therapy reverses atherosclerotic process in mice

First clinical trial of MBI-853NL begins

Campath BLA accepted for filing

Alexion and Brigham & Women's Hospital to develop novel antiinflammatory antibody

Matrix provides development update at BIO CEO

MGI Pharma updates irofulven progress during 1999

Sankyo discovers new antibacterials produced by Streptomyces

Novel vitamin D compounds for cancer, bone disorders

Production, synthesis and activity of new Xenova compounds for immunoinflammatory conditions

Development of cystic fibrosis therapy advances at SciClone

Marine sponges found to produce potent caspase inhibitors

Guanylate cyclase-activating agents in early development at Aventis

Actelion and Genentech to codevelop tezosentan for the U.S. market

Patient dosing begins in phase I study of first anti-HCV ribozyme therapy

Pharmacyclics' texaphyrins now claimed for use in macrophage-mediated conditions

Ganaxolone produces only modest beneficial effects in cerebral hematoma model

Novartis files for U.S., European approval of new IBS treatment

XTL reports on phase I testing of XTL-001 at investor conference

Acute and subchronic testing in mice indicates limited systemic toxicity for GLG-V-13

Itraconazole increases saquinavir exposure in HIV-infected patients, similar to ritonavir

Key development projects on track at Novartis

PDL to humanize Fujisawa antibody

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...